GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xintela AB (OSTO:XINT) » Definitions » Notes Receivable

Xintela AB (OSTO:XINT) Notes Receivable : kr0.00 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Xintela AB Notes Receivable?

Xintela AB's Notes Receivable for the quarter that ended in Mar. 2024 was kr0.00 Mil.


Xintela AB Notes Receivable Historical Data

The historical data trend for Xintela AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xintela AB Notes Receivable Chart

Xintela AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xintela AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Xintela AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Xintela AB Notes Receivable Related Terms

Thank you for viewing the detailed overview of Xintela AB's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Xintela AB (OSTO:XINT) Business Description

Traded in Other Exchanges
N/A
Address
Medicon Village, Lund, SWE, 22381
Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis and antibody-based therapies for Glioblastoma and Tripple-negative breast cancer. XSTEM is also evaluated for the treatment of the severe and deadly lung complication ARDS, which may affect covid-19 patients.

Xintela AB (OSTO:XINT) Headlines

No Headlines